





ثبكة المعلومات الجامعية





جامعة عين شمس

التوثيق الالكتروني والميكروفيلم



نقسم بللله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأفلام قد اعدت دون آية تغيرات



يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15-20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of 15-25c and relative humidity 20-40 %



ثبكة المعلومات الجامعية







Effect of Fosinopril on Some Serum Constituents in Experimentally Induced Diabetes Mellitus in Rats

Thesis Submitted for the Partial Fulfillment of the M.D. Degree in Pharmacology

Presented by: Amani Nabil Shafik

(M.B.B.Ch. - M.Sc Clinical and Chemical Pathology – M.Sc Pharmacology)
Assistant Lecturer
Faculty of Medicine – Cairo university

Supervisors

Professor Dr. Zarif Isaak Girgis

Professor and Chairman of the Department of Pharmacology Faculty of Medicine Cairo University

Professor Dr. Mohamed El Desouky Leheta

Professor of Pharmacology Faculty of Medicine Cairo University

Professor Dr. Gamil Amin Tawadrous

Professor and Chairman of the Department of Medical Biochemistry Faculty of Medicine Cairo University

Faculty of Medicine - Cairo University

13 9 y) \

•
جامعة الغاهرة / كلية الطب النسر الميسمني
أجتماع لجنة الحكم على الرسسالة البقدسة مسسن
Ments out the Cale Marine
توطئة للحصول على درجــة التاجستير / الدكتــــــــــــــــــــــــــــــــــــ
Fflect of Fosinopul on Some Serum: in Experimentally Induced Dialetes Mellitus in Rats.
: باللغة العربية : مَالُسِ "الفورينوبوبل" على بعض مكونات مصل الدم في فيزار " التجارب ذات الموال الكرى
بنا على موافقة الجامعة بتاريخ ٢٠ / ١١٩٨ تم تشكيل لجنة الفحص والمناقشة للرسالة المذكوة أعسلاه على النحي التالمي على النحي المناهرة المدكوة أعسلاه على النحي والتالمي وأرمالولجي وطي المناهرة المستوفين المناهرة ال
١) والسهد المسارطور في المسارطور في المساولين الطب طرال المرق عن المساولين
۲) الن محد همرى محرعلى المستند على المالين والله عيد المالية
بعد فحص الرسالة بواسطة كل عنومنفردا وكتابة تقارير منفردة لكل منهم المدت اللجنة مجتمعه في المال عنهم النام الطويا للا يمم النام الطويا للا يمم النام الطويا للا يمم النام الطويا للا المنام المالية ال
يكلية الطب - جامعة القاهرة وذلك لمناتشة الطالب في جلسة طنية في موضيع الرسالة والنتائج التي توسيل
ب من المسالة والنتائج التي تومسك النتائج التي تجلسه عليه في موماع الرسالة والنتائج التي تومسك المايه ولانتائج التي تومسك المايها ولا الماية التي تام عليها البحث الم
فراراللجنية:للسيدلة حميم من كالمانان على حمده
ولنا فيت الله قد ول السيالة لديم الأتراب
ف الماري المارية
Sully will so I will
توفيعات أعضاء اللجنسة :
المشرف المتحن المتحن الداخلي ، المتحن الخارجي
المنون الناجي المناف المناف الناجي ا

in the second , itali

Acknowledgment

I wish to express my sincere gratitude to my dear Professor, Professor Dr. Zarif Isaak Girgis, Professor and Chairman of the department of pharmacology, Faculty of Medicine, Cairo University, for his help and support throughout this work. His continuous guidance and valuable advice not only in this work but in every aspect are greatly appreciated and dearly cherished. I have learned a great deal from him and hope that one day I can repay him.

I feel extremely indebted to my professor, Professor Dr. Mohamed El-Desouky Leheta, Professor of Pharmacology, Faculty of Medicine, Cairo University. His continuous support and kind collaboration in the supervision of this work are greatly valued. I am thanksful for his precious time, encouragement and kind support.

The credit of all the laboratory work in this thesis goes directly to my professor, **Professor Dr. Gamil Amin Tawadrous**, Professor and Chairman of the Department of Medical Biochemistry, Faculty of Medicine – Cairo University. I need to express him my sincere gratitude, he has been extremely patient and very generous with me. I am deeply touched by his help and concern.

The support of my family and the love of my daughter are the greatest blessing that God has granted me in my life.

I thank God above all for the completion of this work.

Content

	Page
List of Table	
Introduction	1
Review of Literature	3
* The renin-Angiotensin System	3
* Angiotensin-Converting Enzyme (ACE) Inhibit	tors on power words.
* Fosinopril	19
* Diabetes Mellitus	27
* Lipoproteins	42
* Diabetes and Hyperlipidemia	46
Aim of the Work	47
Materials and Methods	48
Results	55
Discussion	88
Summary & Conclusion	98
References	106
Appendix	
Arabic Summary	

Table (18)	Comparison of plasma glucose, serum triglyceride (TG),	77
	total cholesterol (TC), high density lipoprotein cholesterol	
	(HDLc), Total cholesterol/high density lipoprotein	
	cholesterol (TC/HDLc) and low density lipoprotein	
	cholesterol (LDLc) between group V (diabetic + insulin +	
	hypercholesterolemia + 25 mg therapy) and controls	
Table (19)	Comparison of plasma glucose, serum triglyceride (TG),	78
	total cholesterol (TC), high density lipoprotein cholesterol	
	(HDLc), Total cholesterol/high density lipoprotein	
	cholesterol (TC/HDLc) and low density lipoprotein	
	cholesterol, (LDLc) between group VI (diabetic + insulin +	
	hypercholesterolemia + 50mg therapy) and controls	
Table (20)	Comparison of results of 4 weeks therapy with 25 mg/kg	79
	fosinopril versus 4 weeks group IV.	
Table (21)	Comparison of results of 4 weeks therapy with 25 mg/kg	79
	fosinopril versus 8 weeks group IV.	
Table (22)	Comparison of results of 8 weeks therapy with 25 mg/kg	80
	fosinopril versus 4 weeks group IV.	
Table (23)	Comparison of results of 8 weeks therapy with 25 mg/kg	80
	fosinopril versus 8 weeks group IV.	
Table (24)	Comparison of results of 4 weeks therapy with 50 mg/kg	81
	fosinopril versus 4 weeks group IV.	
Table (25)	Comparison of results of 4 weeks therapy with 50 mg/kg	81
	fosinopril versus 8 weeks group IV.	
Table (26)	Comparison of results of 8 weeks therapy with 50 mg/kg	82
	fosinopril versus 4 weeks group IV.	
Table (27)	Comparison of results of 8 weeks therapy with 50 mg/kg	82
	fosinopril versus 8 weeks group IV.	
Γable (28)	Comparison of results of 8 weeks therapy with 25 mg/kg	82
	fosinopril versus 4 weeks therapy with 50mg/kg fosinopril.	

List of Tables

		Page
Table (1)	Plasma glucose levels of group I and group II	69
Table (2)	Serum Triglyceride (TG) levels of group I and group II	69
Table (3)	Serum total cholesterol (TC) levels of group I and group II	70
Table (4)	Serum levels of high density lipoprotein cholesterol	70
	(HDLc) of group I and group II	
Table (5)	Serum total cholesterol / high density lipoprotein	71
	cholesterol (TC/HDLc) ratio of group I and group II	
Table (6)	Serum levels of low density lipoprotein cholesterol (LDLc)	7.1
	of group I and group II	` ,
Γable (7)	Results of variable of group I and group II (Control)	72
Table (8)	Results of variable of group III (4 weeks)	72
(9) Table	Results of variable of group III (8 weeks)	72
Table (10)	Results of variable of group IV (4 weeks)	73
Table (11)	Results of variable of group IV (8 weeks)	73
Table (12)	Results of variable of group V (4 weeks)	73
Γable (13)	Results of variable of group V (8 weeks)	74
Γable (14)	Results of variable of group VI (4 weeks)	74
Table (15)	Results of variable of group VI (8 weeks)	74
Table (16)	Comparison of plasma glucose, serum triglyceride (TG),	75
	total cholesterol (TC), high density lipoprotein cholesterol	
	(HDLc), *Total **cholesterol/laigh **density **dipoprotein	
•	cholesterol (TC/HDLc) and low density lipoprotein	
	cholesterol (LDLc) between group III (diabetic + insulin)	
	and controls	
Table (17)	Comparison of plasma glucose, serum triglyceride (TG),	76
	total cholesterol (TC), high density lipoprotein cholesterol	
	(HDLc), Total cholesterol/high density lipoprotein	
	cholesterol (TC/HDLc) and low density lipoprotein	
	cholesterol (LDLc) between group IV (diabetic + insulin +	
	hyperchalesteralemia) and controls	

Introduction

Diabetes mellitus is a major health care issue. It is not a single disease entity, it is a systemic disease that includes a variety of metabolic disorders (Ziemmet and Kelly, 1992).

The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction and failure of various organs, especially the eyes, kidney, nerves, heart and blood vessels (The Expert Committee on The Diagnosis of D.M., 1997).

Premature cardiovascular disease resulting from accelerated atherosclerosis is one of the most common and serious complications of diabetes (Sharpe et al., 1988).

The frequency of hyperlipidemia in diabetes is indeed very high, depending on the type of diabetes and its degree of control (*Balassa*, 1985). It consists of hypertriglyceridemia with raised VLDL, total cholesterol and LDL.

The class of angiotensin-converting enzyme (ACE) inhibitors has emerged as one of the most important to modern cardiovascular medicine. Its efficacy in the treatment of hypertension, congestive heart failure, ventricular dysfunction and diabetic nephropathy has been established (Krommer et al., 1990; Morgan and Andersson, 1992; Böhlen et al., 1994).

Fosinopril (monopril) is the ester produg of an angiotensin-converting enzyme (ACE) inhibitor, fosinoprilat. It is the first member of a novel chemical class of angiotensin-converting enzyme (ACE) at inhibitors, the phosphinic acids (Hui et al., 1991).

In the present work, the effect of the angiotensin-converting and enzyme (ACE) inhibitor "fosinopril" on the plasma glucose, serum triglyceride, total serum cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol was investigated in experimentally induced type I diabetes mellitus (IDDM) in rats.

The Renin-Angiotensin System

Tiegerstedt and Bergman in 1898, demonstrated that saline extracts of the kidney elicited a very potent pressor response because they contained a pressor substance which they named renin. In 1934, Goldblatt and his colleagues showed that sustained hypertension could be produced by clamping the renal artery of a dog. In 1940, Braun-Menendez and his colleagues in Argentina and Page and Helmer in the United state reported that renin was an enzyme that acted on a piasma protein substrate to catalyze the formation of the actual pressor material, a peptide, which was named hypertensin by the former group and angiotonin by the latter. These two terms persisted for nearly 20 years. until it was agreed to rename the pressor substance angiotensin and to call the plasma substrate angiotensinogen. In the mid-1950s, two forms of angiotensin were recognized, the first a decapeptide (angiotensin I) and the second an octapeptide (angiotensin II) formed by enzymatic cleavage of angiotensin I by another enzyme, termed angiotensin converting enzyme. The octapeptide was shown to be more active form (Skeggs et al., 1954).

Further progress came in 1958, when *Gross* suggested that the renin-angiotensin system was involved in the regulation of aldosterone secretion.

In 1965, *Ferreira* described bradykinin-potentiating factor, which was present in the venom of the Brazilian pit viper, Bothrops Jararaca.